| Species |
Cynomolgus |
| Protein Construction |
TNFR1/CD120a/TNFRSF1A (Leu30-Thr211)
Accession # A0A7N9CVF2 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TNFR1/CD120a/TNFRSF1A, His, Cynomolgus at 2μg/ml (100μl/well) on the plate can bind Biotinylated Human TNF alpha, His Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
21.62 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 32-42 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tumour necrosis factor alpha (TNF-α) is a pleiotropic cytokine with both injurious and protective functions, which are thought to diverge at the level of its two cell surface receptors, TNFR1 and TNFR2. In the setting of acute injury, selective inhibition of TNFR1 is predicted to attenuate the cell death and inflammation associated with TNF-α, while sparing or potentiating the protective effects of TNFR2 signalling. |
| Synonyms |
TNF-R1; TNF-RI; FPF; TBP1; TNF-R55; TNFAR; TNFR60; p55; p60; MS5; p55-R; TNFR1-d2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
